{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T20:29:59Z","timestamp":1786480199228,"version":"build-2736575974"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney360"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:p>Nearly seven decades have elapsed since the clinical and biochemical features of primary hyperaldosteronism (PA) were described by Conn. PA is now widely recognized as the most common form of secondary hypertension. PA has a strong correlation with cardiovascular disease and failure to recognize and\/or properly diagnose this condition has profound health consequences. With proper identification and management, PA has the potential to be surgically cured in a proportion of affected individuals. The diagnostic pursuit for PA is not a simplistic endeavor, particularly because an enhanced understanding of the disease process is continually redefining the diagnostic and treatment algorithm. These new concepts have emerged in all areas of this clinical condition, including identification, diagnosis, and treatment. Here, we review the recent advances in this field and summarize the effect these advances have on both diagnostic and therapeutic modalities.<\/jats:p>","DOI":"10.34067\/kid.0000922020","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T22:39:37Z","timestamp":1595543977000},"page":"1148-1156","source":"Crossref","is-referenced-by-count":5,"title":["Hyperaldosteronism: How Current Concepts Are Transforming the Diagnostic and Therapeutic Paradigm"],"prefix":"10.34067","volume":"1","clinical-trial-number":[{"clinical-trial-number":"nct02169089","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Michael R.","family":"Lattanzio","sequence":"first","affiliation":[{"name":"Division of Nephrology, Department of Medicine, The Chester County Hospital\/University of Pennsylvania Health System, Philadelphia, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8820-5702","authenticated-orcid":false,"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"B1-20230821","first-page":"3","article-title":"Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome","volume":"45","author":"Conn","year":"1955","journal-title":"J Lab Clin Med"},{"key":"B2-20230821","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/jch.12998","article-title":"The Lancet Commission on hypertension: Addressing the global burden of raised blood pressure on current and future generations","volume":"19","author":"O\u2019Brien","year":"2017","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"B3-20230821","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1161\/01.HYP.0000040261.30455.B6","article-title":"Hyperaldosteronism among black and white subjects with resistant hypertension","volume":"40","author":"Calhoun","year":"2002","journal-title":"Hypertension"},{"key":"B4-20230821","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","article-title":"Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: A systematic review and meta-analysis","volume":"6","author":"Monticone","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B5-20230821","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-8587(17)30367-4","article-title":"Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: A retrospective cohort study","volume":"6","author":"Hundemer","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B6-20230821","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1161\/HYPERTENSIONAHA.117.10263","article-title":"Prevalence of cardiovascular disease and its risk factors in primary aldosteronism: A multicenter study in Japan","volume":"71","author":"Ohno","year":"2018","journal-title":"Hypertension"},{"key":"B7-20230821","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1097\/HJH.0000000000002046","article-title":"Assessing the quality of guidelines for primary aldosteronism: Which guidelines are worth applying in diverse settings?","volume":"37","author":"Wu","year":"2019","journal-title":"J Hypertens"},{"key":"B8-20230821","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","article-title":"A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients","volume":"48","author":"Rossi","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B9-20230821","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","article-title":"Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit","volume":"75","author":"Burrello","year":"2020","journal-title":"Hypertension"},{"key":"B10-20230821","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7326\/M20-0065","article-title":"The unrecognized prevalence of primary Aldosteronism: A cross-sectional study","volume":"173","author":"Brown","year":"2020","journal-title":"Ann Intern Med"},{"key":"B11-20230821","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"B12-20230821","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1001\/jamacardio.2018.2003","article-title":"Incidence of atrial fibrillation and mineralocorticoid receptor activity in patients with medically and surgically treated primary aldosteronism","volume":"3","author":"Hundemer","year":"2018","journal-title":"JAMA Cardiol"},{"key":"B13-20230821","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1161\/HYPERTENSIONAHA.117.10596","article-title":"Adrenalectomy lowers incident atrial fibrillation in primary aldosteronism patients at long term","volume":"71","author":"Rossi","year":"2018","journal-title":"Hypertension"},{"key":"B14-20230821","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1378\/chest.125.1.112","article-title":"Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea","volume":"125","author":"Calhoun","year":"2004","journal-title":"Chest"},{"key":"B15-20230821","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/1470320310366581","article-title":"Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism","volume":"11","author":"Di Murro","year":"2010","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"B16-20230821","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/jhh.2013.32","article-title":"Clinical characteristics of patients with resistant hypertension: The RESIST-POL study","volume":"27","author":"Florczak","year":"2013","journal-title":"J Hum Hypertens"},{"key":"B17-20230821","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/thx.2006.071183","article-title":"Alterations in upper airway cross-sectional area in response to lower body positive pressure in healthy subjects","volume":"62","author":"Shiota","year":"2007","journal-title":"Thorax"},{"key":"B18-20230821","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/jhh.2011.47","article-title":"Resistant hypertension, obstructive sleep apnoea and aldosterone","volume":"26","author":"Dudenbostel","year":"2012","journal-title":"J Hum Hypertension"},{"key":"B19-20230821","doi-asserted-by":"crossref","first-page":"464","DOI":"10.3109\/10641963.2015.1131290","article-title":"Effect of spironolactone on patients with resistant hypertension and obstructive sleep apnea","volume":"38","author":"Yang","year":"2016","journal-title":"Clin Exp Hypertens"},{"key":"B20-20230821","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/jhh.2017.28","volume":"31","author":"Wolley","year":"2017","journal-title":"J Hum Hypertension"},{"key":"B21-20230821","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1210\/jc.2015-4061","article-title":"The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline","volume":"101","author":"Funder","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B22-20230821","doi-asserted-by":"crossref","first-page":"e005574","DOI":"10.1161\/JAHA.117.005574","article-title":"Quantitative value of aldosterone-renin ratio for detection of aldosterone-producing adenoma: The aldosterone-renin ratio for primary aldosteronism (AQUARR) study","volume":"6","author":"Maiolino","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"B23-20230821","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/ajh\/3.7.576","article-title":"Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma","volume":"3","author":"Irony","year":"1990","journal-title":"Am J Hypertens"},{"key":"B24-20230821","first-page":"522","article-title":"Primary aldosteronism with normal aldosterone levels in blood and urine","volume":"110","author":"Nomura","year":"1985","journal-title":"Acta Endocrinol (Copenh)"},{"key":"B25-20230821","first-page":"28","article-title":"Increased disorderliness and amplified basal and pulsatile aldosterone secretion in patients with primary aldosteronism","volume":"80","author":"Siragy","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"B26-20230821","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1210\/jc.2016-1963","article-title":"Dietary sodium restriction increases the risk of misinterpreting mild cases of primary aldosteronism","volume":"101","author":"Baudrand","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"B27-20230821","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/HYPERTENSIONAHA.118.11014","article-title":"Age-related blood pressure sensitivity to aldosterone in blacks and whites","volume":"72","author":"Tu","year":"2018","journal-title":"Hypertension"},{"key":"B28-20230821","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2214\/ajr.160.2.8424342","article-title":"CT in the diagnosis of primary aldosteronism: Sensitivity in 29 patients","volume":"160","author":"Dunnick","year":"1993","journal-title":"AJR Am J Roentgenol"},{"key":"B29-20230821","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.surg.2004.06.051","article-title":"Role for adrenal venous sampling in primary aldosteronism","volume":"136","author":"Young","year":"2004","journal-title":"Surgery"},{"key":"B30-20230821","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-151-5-200909010-00007","article-title":"Systematic review: Diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism","volume":"151","author":"Kempers","year":"2009","journal-title":"Ann Intern Med"},{"key":"B31-20230821","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S2213-8587(17)30135-3","article-title":"Outcomes after adrenalectomy for unilateral primary aldosteronism: An international consensus on outcome measures and analysis of remission rates in an international cohort","volume":"5","author":"Williams","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B32-20230821","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1007\/s00330-004-2308-2","article-title":"Diagnostic performance of CT versus MR in detecting aldosterone-producing adenoma in primary hyperaldosteronism (Conn\u2019s syndrome)","volume":"14","author":"Lingam","year":"2004","journal-title":"Eur Radiol"},{"key":"B33-20230821","first-page":"1066","article-title":"Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism","volume":"86","author":"Magill","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"B34-20230821","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/eci.12746","article-title":"Accuracy of adrenal imaging and adrenal venous sampling in diagnosing unilateral primary aldosteronism","volume":"47","author":"Ladurner","year":"2017","journal-title":"Eur J Clin Invest"},{"key":"B35-20230821","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1089\/end.2008.0007","article-title":"Usefulness of adrenal vein sampling in the evaluation of aldosteronism","volume":"22","author":"Schwab","year":"2008","journal-title":"J Endourol"},{"key":"B36-20230821","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1210\/jc.2011-2830","article-title":"The Adrenal Vein Sampling International Study (AVIS) for identifying the major subtypes of primary aldosteronism","volume":"97","author":"Rossi","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"B37-20230821","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2213-8587(16)30100-0","article-title":"Adrenal vein sampling versus CT scan to determine treatment in primary aldosteronism: An outcome-based randomised diagnostic trial","volume":"4","author":"Dekkers","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B38-20230821","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/HYPERTENSIONAHA.116.08820","article-title":"Adrenal venous sampling versus computed tomographic scan to determine treatment in primary aldosteronism (the SPARTACUS trial): A critique","volume":"69","author":"Rossi","year":"2017","journal-title":"Hypertension"},{"key":"B39-20230821","doi-asserted-by":"crossref","first-page":"630","DOI":"10.7326\/M17-0882","article-title":"The spectrum of subclinical primary aldosteronism and incident hypertension: A cohort study","volume":"167","author":"Brown","year":"2017","journal-title":"Ann Intern Med"},{"key":"B40-20230821","doi-asserted-by":"crossref","first-page":"104","DOI":"10.9738\/CC140.1","article-title":"Predictors of successful outcome after adrenalectomy for primary aldosteronism","volume":"97","author":"Wang","year":"2012","journal-title":"Int Surg"},{"key":"B41-20230821","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1126\/science.1198785","article-title":"K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension","volume":"331","author":"Choi","year":"2011","journal-title":"Science"},{"key":"B42-20230821","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1161\/HYPERTENSIONAHA.111.186478","article-title":"Prevalence, clinical, and molecular correlates of KCNJ5 mutations in primary aldosteronism","volume":"59","author":"Boulkroun","year":"2012","journal-title":"Hypertension"},{"key":"B43-20230821","doi-asserted-by":"crossref","first-page":"E4591","DOI":"10.1073\/pnas.1505529112","article-title":"Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands","volume":"112","author":"Nishimoto","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B44-20230821","doi-asserted-by":"crossref","first-page":"11396","DOI":"10.1038\/srep11396","article-title":"Prevalence and clinical correlates of somatic mutation in aldosterone producing adenoma-Taiwanese population","volume":"5","author":"Wu","year":"2015","journal-title":"Sci Rep"},{"key":"B45-20230821","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1507\/endocrj.EJ16-0243","article-title":"Characteristics of Japanese aldosterone-producing adenomas with KCNJ5 mutations","volume":"64","author":"Okamura","year":"2017","journal-title":"Endocr J"},{"key":"B46-20230821","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/ng.2695","article-title":"Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism","volume":"45","author":"Scholl","year":"2013","journal-title":"Nat Genet"},{"key":"B47-20230821","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1210\/jc.2019-00531","article-title":"KCNJ5 somatic mutation is a predictor of hypertension remission after adrenalectomy for unilateral primary aldosteronism","volume":"104","author":"Vilela","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"B48-20230821","doi-asserted-by":"crossref","first-page":"29984","DOI":"10.18632\/oncotarget.16269","article-title":"Arterial stiffness and blood pressure improvement in aldosterone-producing adenoma harboring KCNJ5 mutations after adrenalectomy","volume":"8","author":"Chang","year":"2017","journal-title":"Oncotarget"},{"key":"B49-20230821","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1172\/JCI91733","article-title":"Macrolides selectively inhibit mutant KCNJ5 potassium channels that cause aldosterone-producing adenoma","volume":"127","author":"Scholl","year":"2017","journal-title":"J clin invest"},{"key":"B50-20230821","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1161\/HYPERTENSIONAHA.117.10226","article-title":"Macrolides blunt aldosterone biosynthesis: A proof-of-concept study in KCNJ5 mutated adenoma cells ex vivo","volume":"70","author":"Caroccia","year":"2017","journal-title":"Hypertension"},{"key":"B51-20230821","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","article-title":"Esaxerenone: First global approval","volume":"79","author":"Duggan","year":"2019","journal-title":"Drugs"},{"key":"B52-20230821","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"B53-20230821","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2015.1059819","article-title":"Finerenone\u2009: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease","volume":"24","author":"Liu","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"B54-20230821","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"B55-20230821","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B56-20230821","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cjca.2012.04.014","article-title":"Effects of aldosterone on human atherosclerosis: Plasma aldosterone and progression of carotid plaque","volume":"28","author":"de Rita","year":"2012","journal-title":"Can J Cardiol"},{"key":"B57-20230821","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000480652","article-title":"The role of the mineralocorticoid receptor in inflammation: focus on kidney and vasculature","volume":"46","author":"Belden","year":"2017","journal-title":"Am J Nephrol"},{"key":"B58-20230821","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"B59-20230821","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/clc.22718","article-title":"Design of the magnetic resonance imaging evaluation of mineralocorticoid receptor antagonism in diabetic atherosclerosis (MAGMA) trial","volume":"40","author":"Rajagopolan","year":"2017","journal-title":"Clin Cardiol"}],"container-title":["Kidney360"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000922020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T19:57:07Z","timestamp":1786478227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.34067\/KID.0000922020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":59,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.34067\/kid.0000922020","relation":{},"ISSN":["2641-7650"],"issn-type":[{"value":"2641-7650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10]]}}}